At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 9 enrolled
Drug / intervention
OCV-501 +2 moredrug
Likely dose
OCV-501 0.3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study of OCV-501 in the Treatment of Patients With Acute Myeloid Leukemia
In Brief
A Phase 1 clinical trial evaluating OCV-501 for Acute Myeloid Leukemia. Completed, enrolled 9 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the safety, tolerability of OCV-501 in patients with acute myeloid leukemia (AML) who achieved complete remission after induction regimen and who completed a standard consolidation therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2011
First PostedSep 2011
Primary CompletionMar 2013
Study CompletionJul 2013
TodayJul 2026
First PostedSep 27, 2011
Enrollment StartSep 1, 2011
Primary CompletionMar 1, 2013
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.8 years ago
Interventions
OCV-501drug
subcutaneously administered once a week, 4 times at the dose of 0.3 mg
OCV-501drug
subcutaneously administered once a week, 4 times at the dose of 1 mg
OCV-501drug
subcutaneously administered once a week, 4 times at the dose of 3 mg